Richard A. Larson to Immunologic Factors
This is a "connection" page, showing publications Richard A. Larson has written about Immunologic Factors.
Connection Strength
0.086
-
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res. 2002 Sep; 8(9):2812-9.
Score: 0.047
-
Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients. Leuk Lymphoma. 1993 Jun; 10(3):183-6.
Score: 0.025
-
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006 Jan 20; 24(3):437-43.
Score: 0.015